Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the monoclonal antibody Nirsevimab, which was approved by the Medicines and Healthcare products Regulatory Agency in November 2022; and when it will be made available to patients on the NHS.

The Joint Committee on Vaccination and Immunisation (JCVI) is actively reviewing new and emerging products to provide immunisation against Respiratory Syncytial Virus, including the monoclonal antibody Nirsevimab. Once the JCVI concludes their review of evidence and modelling, the Government will consider their recommendations and whether to implement changes to the immunisation products offered by the National Health Service in due course.